Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics. The Company's clinical stage drug candidate, ganaxolone, is a novel synthetic analog of the endogenous neurosteroid, allopregnanolone. Ganaxolone is known for its anticonvulsive and antianxiety effects, and was designed to avoid hormonal side-effects associated with endogenous neurosteroids. Ganaxolone is presently being studied in a multinational, randomized, placebo-controlled, Phase 2B/3 clinical trial in adult subjects for adjunctive treatment of partial-onset seizures. The Company currently has a Phase 2 proof-of-concept pediatric clinical trial in progress for ganaxolone as a treatment for behaviors in Fragile X Syndrome and is initiating a Phase 2 proof-of-concept clinical study later this year for the treatment of PCDH19 female pediatric epilepsy. Both Fragile X Syndrome and PCDH19 female pediatric epilepsy are potential orphan disorders that have been related to mutations affecting neurosteroid signaling at extrasynaptic GABA A receptors.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics. The Company's clinical stage drug candidate, ganaxolone, is a novel synthetic analog of the endogenous neurosteroid, allopregnanolone. Ganaxolone is known for its anticonvulsive and antianxiety effects, and was designed to avoid hormonal side-effects associated with endogenous neurosteroids. Ganaxolone is presently being studied in a multinational, randomized, placebo-controlled, Phase 2B/3 clinical trial in adult subjects for adjunctive treatment of partial-onset seizures. The Company currently has a Phase 2 proof-of-concept pediatric clinical trial in progress for ganaxolone as a treatment for behaviors in Fragile X Syndrome and is initiating a Phase 2 proof-of-concept clinical study later this year for the treatment of PCDH19 female pediatric epilepsy. Both Fragile X Syndrome and PCDH19 female pediatric epilepsy are potential orphan disorders that have been related to mutations affecting neurosteroid signaling at extrasynaptic GABA A receptors.
Top 10 Most Recent Blog Posts
The Role of Technology in Mortgage Referral Programs
Category: Real Estate Total Views: 207By : Editor Updated: 05-29-2024
Why Your Business Emails Land in Spam and How to Fix It
Category: Business Total Views: 205By : Editor Updated: 05-29-2024
7 Small Business Functions That you can Outsource
Category: Business Total Views: 181By : Editor Updated: 05-29-2024
The Future of Green Energy Stocks in 2024
Category: Stocks Total Views: 184By : Editor Updated: 05-28-2024
Canopy Growth Corp. (CGC): Research Report June 2024
Category: Stocks Total Views: 182By : Editor Updated: 05-28-2024
Top 10 Small Business Trends to Watch in 2024
Category: Business Total Views: 159By : Editor Updated: 05-28-2024
Mullen Automotive, Inc. (MULN): Research Report June 2024
Category: Stocks Total Views: 220By : Editor Updated: 05-28-2024
Commercial Real Estate: Managing Interest Rates in 2024
Category: Real Estate Total Views: 292By : Editor Updated: 05-27-2024
Market Trends & Sector Outlook: What to Watch in June 2024
Category: Markets Total Views: 365By : Editor Updated: 05-27-2024
Top Financial Goals for 2024 and How to Achieve Them
Category: Personal Finance Total Views: 250By : Editor Updated: 05-27-2024